Guillermo Garcia-Manero, MD
Articles
Trial To Evaluate Eprenetapopt-Azacytidine Combo in TP53+ MDS Completes Enrollment
June 18, 2020
Video
A phase 3 trial designed to evaluate eprenetapopt plus azacytidine (Vidaza) in patients with TP53-mutant positive myelodysplastic syndrome (MDS) completed full enrollment, according to Aprea Therapeutics, Inc.